Stoke Therapeutics STOK

$ 13.1 0.0%

Quarterly report 2024-Q2
added 08-07-2024

Stoke Therapeutics Financial Statements 2011-2024 | STOK

Annual Financial Statements Stoke Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	286 M	349 M	716 M	2.03 B	501 M	36.3 B	-	-	-	-	-	-	-
Shares	44 M	38.9 M	36.7 M	33.3 M	18 M	30.3 M	-	-	-	-	-	-	-
Historical Prices	6.5	8.97	19.5	59.9	24.8	-	-	-	-	-	-	-	-
Net Income	-105 M	-101 M	-85.8 M	-52.2 M	-32.3 M	-12.5 M	-5.56 M	-	-	-	-	-	-
Revenue	8.78 M	12.4 M	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-115 M	-104 M	-86.1 M	-53 M	-35.7 M	-12.8 M	-	-	-	-	-	-	-
Interest Expense	166 K	167 K	140 K	101 K	2 K	-10 K	-	-	-	-	-	-	-
EBITDA	-112 M	-103 M	-85.1 M	-52.2 M	-35.2 M	-12.6 M	-5.44 M	-	-	-	-	-	-
Operating Expenses	124 M	117 M	86.1 M	53 M	35.7 M	-	-	-	-	-	-	-	-
General and Administrative Expenses	41.3 M	38.9 M	31.9 M	20.8 M	11.9 M	4.41 M	1.96 M	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Stoke Therapeutics

	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	55.8 M	46.2 M	45.9 M	44.3 M	44.2 M	42.5 M	39.4 M	39.4 M	39.3 M	37.4 M	36.9 M	36.8 M	36.7 M	36.6 M	36.6 M	33.3 M	33.1 M	32.9 M	32.9 M	32.7 M	5.08 M	833 K	727 K	699 K	691 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-25.7 M	-26.4 M	-	-24.5 M	-30.7 M	-22.5 M	-	-26.1 M	-24.7 M	-24.6 M	-	-22.6 M	-22 M	-16.8 M	-14.6 M	-13.7 M	-13 M	-11 M	-10.2 M	-8.6 M	-7.82 M	-5.74 M	-4.28 M	-3.32 M	-3.01 M	-1.91 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	4.83 M	4.22 M	-	3.31 M	-2.48 M	5.15 M	-	2.9 M	3.23 M	3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-29.3 M	-28.4 M	-	-27.2 M	-33.3 M	-24.7 M	-	-27.1 M	-25.2 M	-24.8 M	-	-22.7 M	-22 M	-16.8 M	-14.6 M	-13.7 M	-13 M	-11.7 M	-11.1 M	-9.84 M	-8.44 M	-6.32 M	-4.54 M	-3.32 M	-3.01 M	-1.91 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-48 K	-428 K	-	41 K	41 K	42 K	-	42 K	42 K	42 K	-	42 K	28 K	28 K	-	28 K	14 K	22 K	-	2 K	-3 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-27.8 M	-	-	-	-24.1 M	-	-26.2 M	-24.7 M	-24.5 M	-	-21.9 M	-21.5 M	-16.6 M	-14.6 M	-13.1 M	-12.6 M	-11.5 M	-11.1 M	-9.53 M	-8.26 M	-6.24 M	-4.54 M	-3.18 M	-2.94 M	-1.91 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	34.2 M	32.6 M	-	30.5 M	30.8 M	29.8 M	-	30.1 M	28.5 M	27.8 M	-	22.7 M	22 M	16.8 M	14.6 M	13.7 M	13 M	11.7 M	11.1 M	9.84 M	8.44 M	6.32 M	4.54 M	3.32 M	3.01 M	1.91 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	13 M	10.2 M	-	10.3 M	10.2 M	10.2 M	-	9.94 M	10.1 M	9.49 M	-	8.32 M	7.93 M	6.91 M	-	5.6 M	5.04 M	4.52 M	-	3.32 M	2.42 M	2.19 M	-	1.09 M	1.12 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency